Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CARLSMED, INC.CARL · Entity 5551 | Director · CEO, President | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CARLSMED, INC.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,550,477 |
Ending reported balance
After 2026-03-03 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-03-02 · Exercise / conversion · Acquired 197,855 · Balance 1,554,501 Row 2 · 2026-03-02 · Sale · Disposed 197,855 · Balance 1,356,646 F1: Sale of shares to cover the exercise price, withholding tax obligations and broker fees and commissions, pursuant to a broker assisted cashless exercise of vested stock options granted on January 8, 2021 and February 19, 2025 under the Carlsmed, Inc. 2019 Stock Incentive Plan. F2: This transaction was executed in multiple trades at prices ranging from $13.000 to $14.030. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2026-03-03 · Exercise / conversion · Acquired 160,567 · Balance 1,517,213 Row 4 · 2026-03-03 · Exercise / conversion · Acquired 33,264 · Balance 1,550,477 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.34 · Expires 2031-01-07 | Direct | 160,567 |
Reported balance
After 2026-03-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-02 · Exercise / conversion · Disposed 197,855 · Balance 160,567 F3: 25% of the shares underlying these options, representing a right to purchase a total of 358,422 shares, vested and became exercisable on December 15, 2021, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.34 · Expires 2031-01-07 | Direct | 0 |
Reported balance
After 2026-03-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-03 · Exercise / conversion · Disposed 160,567 · Balance 0 F3: 25% of the shares underlying these options, representing a right to purchase a total of 358,422 shares, vested and became exercisable on December 15, 2021, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.35 · Expires 2035-02-18 | Direct | 191,692 |
Reported balance
After 2026-03-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-03 · Exercise / conversion · Disposed 33,264 · Balance 191,692 F4: 25% of the shares underlying these options, representing a right to purchase a total of 224,956 shares, vested and became exercisable on December 15, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares to cover the exercise price, withholding tax obligations and broker fees and commissions, pursuant to a broker assisted cashless exercise of vested stock options granted on January 8, 2021 and February 19, 2025 under the Carlsmed, Inc. 2019 Stock Incentive Plan.
F2: This transaction was executed in multiple trades at prices ranging from $13.000 to $14.030. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: 25% of the shares underlying these options, representing a right to purchase a total of 358,422 shares, vested and became exercisable on December 15, 2021, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F4: 25% of the shares underlying these options, representing a right to purchase a total of 224,956 shares, vested and became exercisable on December 15, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2026 Filed Mar 4, 2026 21:05 UTC | CARLSMED, INC. CARL · Entity 5551 | Exercise / conversionStock Option (Right to Buy) · Derivative | 33,264 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001193125-26-091468 · ownership.xml · derivative · entry 7 Cordonnier Michael · CIK 0002077087 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,692 Underlying: Common Stock · 33,264 shares Expires 2035-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares underlying these options, representing a right to purchase a total of 224,956 shares, vested and became exercisable on December 15, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 21:05 UTC | CARLSMED, INC. CARL · Entity 5551 | Exercise / conversionStock Option (Right to Buy) · Derivative | 160,567 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001193125-26-091468 · ownership.xml · derivative · entry 6 Cordonnier Michael · CIK 0002077087 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 160,567 shares Expires 2031-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares underlying these options, representing a right to purchase a total of 358,422 shares, vested and became exercisable on December 15, 2021, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 21:05 UTC | CARLSMED, INC. CARL · Entity 5551 | Exercise / conversionCommon Stock | 33,264 | $4.35 | $144,764.93 |
DisclosureSEC source: 0001193125-26-091468 · ownership.xml · nonDerivative · entry 4 Cordonnier Michael · CIK 0002077087 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,550,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 21:05 UTC | CARLSMED, INC. CARL · Entity 5551 | Exercise / conversionCommon Stock | 160,567 | $0.34 | $53,789.95 |
DisclosureSEC source: 0001193125-26-091468 · ownership.xml · nonDerivative · entry 3 Cordonnier Michael · CIK 0002077087 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,517,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:05 UTC | CARLSMED, INC. CARL · Entity 5551 | Exercise / conversionStock Option (Right to Buy) · Derivative | 197,855 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001193125-26-091468 · ownership.xml · derivative · entry 5 Cordonnier Michael · CIK 0002077087 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,567 Underlying: Common Stock · 197,855 shares Expires 2031-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares underlying these options, representing a right to purchase a total of 358,422 shares, vested and became exercisable on December 15, 2021, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:05 UTC | CARLSMED, INC. CARL · Entity 5551 | SaleCommon Stock | 197,855 | $13.29 | $2,629,888.66 |
DisclosureSEC source: 0001193125-26-091468 · ownership.xml · nonDerivative · entry 2 Cordonnier Michael · CIK 0002077087 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,356,646 F1 · shares: Sale of shares to cover the exercise price, withholding tax obligations and broker fees and commissions, pursuant to a broker assisted cashless exercise of vested stock options granted on January 8, 2021 and February 19, 2025 under the Carlsmed, Inc. 2019 Stock Incentive Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.000 to $14.030. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:05 UTC | CARLSMED, INC. CARL · Entity 5551 | Exercise / conversionCommon Stock | 197,855 | $0.34 | $66,281.43 |
DisclosureSEC source: 0001193125-26-091468 · ownership.xml · nonDerivative · entry 1 Cordonnier Michael · CIK 0002077087 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,554,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2026 Filed Jan 30, 2026 22:22 UTC | CARLSMED, INC. CARL · Entity 5551 | GrantCommon Stock | 117,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-032071 · ownership.xml · nonDerivative · entry 1 Cordonnier Michael · CIK 0002077087 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,356,646 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:33 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionSeries B Preferred Stock · Derivative | 3,612 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-098544 · ownership.xml · derivative · entry 3 Cordonnier Michael · CIK 0002077087 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,612 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F1 · price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F1 · derivative.exercise_date: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F1 · derivative.expiration_date: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:33 UTC | CARLSMED, INC. CARL · Entity 5551 | Exercise / conversionCommon Stock | 3,612 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-098544 · ownership.xml · nonDerivative · entry 1 Cordonnier Michael · CIK 0002077087 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,239,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. Read SEC document |
| July 22, 2025 Filed Jul 25, 2025 00:33 UTC | CARLSMED, INC. CARL · Entity 5551 | GrantStock Options (Right to Buy) · Derivative | 142,857 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0000950170-25-098544 · ownership.xml · derivative · entry 2 Cordonnier Michael · CIK 0002077087 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 726,235 Underlying: Common Stock · 142,857 shares Expires 2035-07-09 F2 · derivative.exercise_date: The unvested stock options are convertible into approximately 142,857 shares of the Issuer's common stock and will begin to vest in equal installments on each quarterly anniversary of July 22, 2025 (the "Grant Date"), such that all of the stock options will be vested on the fourth anniversary of the Grant Date, provided that the Reporting Person remains in continuous service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.